World's Best Scientists 2026 revealed!
Patricia LoRusso

Patricia LoRusso

D-Index & Metrics

Medicine

D-Index
97
Citations
44393
World Ranking
9137
National Ranking
4712

Patricia LoRusso publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Patricia LoRusso sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 717 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Patricia LoRusso D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Patricia LoRusso sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Patricia LoRusso is affiliated with Yale University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily focused on oncology, with particular attention to molecular biology, pulmonary and respiratory medicine, immunology, and radiology, nuclear medicine, and imaging.

The scientist's work covers multiple specialized topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • PARP inhibition in cancer therapy
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Immunotherapy and Immune Responses
  • Advanced Breast Cancer Therapies

Frequent publication venues for LoRusso include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Regular and Young Investigator Award Abstracts

Notable recent papers authored or co-authored by Patricia LoRusso are:

  • Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 (2020, CHEST Journal)
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2020, Annals of Oncology)
  • A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma (2020, British Journal of Cancer)
  • Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials (2020, British Journal of Cancer)
  • Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2023, Nature Medicine)

Their frequent collaborators include Geoffrey I. Shapiro, S. Percy Ivy, Yu Shyr, Erika Hamilton, and Joseph P. Eder. These co-authorships indicate an extensive network of research partnerships, with the highest collaboration count being 18 papers with Geoffrey I. Shapiro.

Patricia LoRusso's primary fields of study consist of medicine and biochemistry, genetics, and molecular biology, with a total of 373 publications in medicine and 141 in molecular biology-related fields. Subfields related to cancer research dominate their portfolio, reflective of the focus on oncology and associated biological and medical specialties.

The scientist has also been recognized as a member of the Association of American Physicians, an acknowledgment of professional standing within the medical research community.

Best Publications

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy

  • Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Jeffrey Hrkach;Daniel Von Hoff;Mir Mukkaram Ali;Elizaveta Andrianova

  • Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

    Charles M. Rudin;Christine L. Hann;John Laterra;Robert L. Yauch

  • Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

    Joseph McLaughlin;Gang Han;Kurt A. Schalper;Daniel Carvajal-Hausdorf

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio González-Martín;Patricia M LoRusso

  • Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

    Roy S. Herbst;Anne-Marie Maddox;Mace L. Rothenberg;Eric J. Small

  • Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

    Joseph Paul Eder;George F. Vande Woude;Scott A. Boerner;Patricia M. LoRusso

  • Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

    Joan Albanell;Federico Rojo;Steve Averbuch;Andrea Feyereislova

  • Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

    Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy;Raoul Tibes

  • Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

    Patricia M. LoRusso;Denise Weiss;Ellie Guardino;Sandhya Girish

  • Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

    Patricia M. LoRusso;Alex A. Adjei;Mary Varterasian;Shirish Gadgeel

  • Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio Gonzalez Martin;Patricia M LoRusso

  • Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.

    Tianling Chen;James Berenson;Robert Vescio;Regina Swift

  • A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

    Ian E. Krop;Patricia LoRusso;Kathy D. Miller;Shanu Modi

  • Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

    Patricia Mucci LoRusso

  • 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer

    Helen Lee;Anthony F. Shields;Barry A. Siegel;Kathy D. Miller

  • Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.

    Robert H. Vonderheide;Patricia M. LoRusso;Magi Khalil;Elaina M. Gartner

Frequent Co-Authors

Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
Anthony W. Tolcher
Anthony W. Tolcher Texas Oncology
Ian E. Krop
Ian E. Krop Harvard University
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Amita Patnaik
Amita Patnaik University of Chicago
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in pursuing healthcare careers beyond traditional medical school, there are many flexible online degree options. For those aiming for leadership roles in nursing, considering the easiest online dnp programs can provide a streamlined path to becoming a Doctor of Nursing Practice.

If you are looking to launch your healthcare journey more quickly, an accelerated lpn program allows you to become a Licensed Practical Nurse in less time. Mental health professionals can expand their scope of practice and impact by exploring online msn pmhnp programs that train psychiatric-mental health nurse practitioners.

For those interested in the business and administration side of healthcare, online healthcare administration programs offer a flexible route to leadership positions in hospitals, clinics, and healthcare organizations.

Whether your goal is clinical practice or healthcare management, online degrees create new pathways to meaningful and high-demand career options across the industry.

Best Scientists Citing Patricia LoRusso

Trending Scientists

Recently Published Articles